Neumora Therapeutics Inc.
(NASDAQ:NMRA) on Monday said it is discontinuing development of its lead depression candidate, navacaprant, after two Phase 3 studies failed to achieve statistical significance on both primary and key secondary endpoints in patients with major depressive disorder (MDD).
The clinical-stage biopharmaceutical company said it will now focus on advancing the rest of its pipeline while implementing cost-cutting measures aimed at extending its cash runway.
Read Also: Neumora Therapeutics Stock Jumps, Analyst Sees Upside In Alzheimer's Treatment Phase 3 Studies Fall Short The Phase 3 KOASTAL-2 and KOASTAL-3 trials enrolled 430 and 422 adults with MDD, respectively.
Both studies evaluated navacaprant 80 mg against placebo, with the primary endpoint measuring change from baseline to Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS).
